Skip to content

Netherlands logo

Main menu
    • About us
    • Our focus
    • Our products
    • Business development
    • Our leaders
    • Our culture
    • Policies & positions
    • Environmental, social & governance
    • Diversity, equity, inclusion & belonging
    • News
    • Media
  • Join our team

Contact Us

Back
Change Language
  • Nederlands
Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Organon Launches as New Women’s Health Company

Save Print

June 3, 2021 2:00 pm EDT

AMSTERDAM / BRUSSELS – Organon (NYSE: OGN), today celebrates its launch as the only global company of its size focused on women’s health. The well-known name Organon is back. This is good news for women around the world and good news for the production of medicines in the Netherlands and Belgium – where the global healthcare company has two production sites and two office locations.

‘Launch Day’ in Oss with Petra Willems (Organon Benelux, left), The mayor of Oss Wobine Buijs (Oss), Wenny Raaijmakers (Organon Oss) and Frank den Brok (municipality of Oss).
Production Organon in Heist
‘Launch Day’ in Oss

“Today we are not only launching a new company, today we are launching a commitment to the health of women worldwide. A commitment to listen to women, to understand ‘her’ health needs and help identify solutions that are urgently needed”, according to Petra Willems, who has been appointed Managing Director Organon Benelux. “It’s a unique opportunity to build a new company that intends to be leading in women’s health, to address the needs and conditions that only or disproportionately impact women. Providing a healthier future for women also means providing a healthier future for their families and the communities they are part of around the world.”

Organon started as a pharmaceutical company almost a hundred years ago. The roots in the birthplace Oss are still there, but the new Organon is different: no other large global healthcare company has the health of women as its primary therapeutic area of focus. Petra: “Improving women’s health is critical to achieving a healthier world. Women make up more than half of the world’s population. As a new company, we will begin by listening to women’s healthcare needs to drive our product development – to create and deliver new solutions. Our impact will extend beyond medicines and reproductive health. Because we know there is so much more we can do for women and their health.”

Prof. Dr. Angela Maas (cardiologist and professor of Cardiology for Women, Radboud UMC): “Look at the life-course of women. Every phase has its own needs that are important for women’s health and they are often connected to each other. Good health for women also affects their children, family members, parents, and colleagues at work. Good health is needed to engage in work and to gain more economic independency. Healthy women are the basis for a more equal and better life for all of us.”

“Our legacy for the next generation of girls and women is that every girl, every woman has the right to access good quality healthcare throughout her lifetime”, says Prof. Dr. Marleen Temmerman, currently Chair of the Department of Obstetrics and Gynecology at Aga Khan University Hospital in Nairobi, Kenya. “So many women and girls dying every day of preventable complications of pregnancy is just unacceptable. This is a priority.”

2,000 Organon Benelux employees at four locations
Today, the Organon executive leadership team rings the opening bell at the New York Stock Exchange (NYSE) to mark the first day of active trading. At launch, Organon’s portfolio will consist of more than 60 medicines serving people in more than 140 countries, with nearly 80 percent of its 6.5 billion dollar in revenue generated outside the U.S. Organon has three core pillars that will benefit from renewed management focus and commercial investment: Women’s Health, Biosimilars and Established Brands. Petra: “The diversity of this portfolio will ensure moderate, sustainable growth, so that – together with our partners – we can continue to invest and progress with new medicines and solutions so urgently needed for women. We will serve as a global incubator – of ideas, of science and technology, of collaboration – to actualize innovation and, together with our partners, reshape women’s health.”

From the start today, Organon Benelux delivers important therapies across the world, with a substantial international commercial footprint and world-class production facilities for the global market. Of its approximately 9,000 employees worldwide, around 2,000 work either at one of the trusted production sites in Oss (NL) and Heist-op-den-Berg (Belgium) or in the Benelux commercial offices in Amsterdam and Brussels. Organon’s commitment to improving women’s health is also evident from the number of female leaders in the company. The representation of women on our Board — comprising 70% of positions — is higher than any S&P 500 healthcare company

Petra Willems is an experienced business leader with a long and successful 30-year track record in MSD across many therapeutic areas. Over the years she has held various roles with increasing responsibilities. The last ten years she has been part of the Human Health Management Team of MSD in The Netherlands, serving in five different Director roles, among others as Director Primary Care, Director Immunology & Vaccines and Director External Affairs.
About her appointment, Petra says: “It is a unique opportunity to be able to build a new company with a culture characterized by entrepreneurship, empowerment and inclusiveness. I am very much looking forward to working together with an inspired, driven and effective team in Belgium, the Netherlands and Luxembourg for a successful and bright future, for both Organon and women around the world.”   

What can we help you find?

Search for:
Netherlands logo
  • Forward-Looking Statement
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept